City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  385  Clinical trial(s) found  (Page 1 of 16 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 18065 ClinicalTrials.gov Number: NCT03007147

Principal Investigator: Weili Sun, MD, PhD
Sponsor: Cooperative Group

Title:  COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

COH Protocol Number: 18044

Principal Investigator: Victoria Seewaldt, MD
Sponsor: Institutional

Title:  Reducing Cancer and Chronic Disease Risk in Underserved Communities: Eat, Move, Live Community Program

COH Protocol Number: 18030 ClinicalTrials.gov Number: NCT03258554

Principal Investigator: Sagus Sampath, MD
Sponsor: Cooperative Group

Title:  NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

COH Protocol Number: 18011

Principal Investigator: Lily Lai, MD
Sponsor: Institutional

Title:  Application of Neural Networks to Improve on Polyp Discrimination at Colonoscopy: A Pilot Study

COH Protocol Number: 17509 ClinicalTrials.gov Number: NCT03439280

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenecity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 17505 ClinicalTrials.gov Number: NCT03494569

Principal Investigator: Monzr Al malki, MD
Sponsor: Institutional

Title:  Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined with Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome

COH Protocol Number: 17502 ClinicalTrials.gov Number: NCT03422627

Principal Investigator: Amandeep Salhotra, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease

COH Protocol Number: 17496

Principal Investigator: Benjamin Djulbegovic, MD
Sponsor: NCI Approved External Peer Review

Title:  Evaluation of the Group Decision-making Process of Clinical Guidelines Panels

COH Protocol Number: 17494 ClinicalTrials.gov Number: NCT03384940

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 2, Multicenter, Open-Label Study of DS-8201a in Subjects with HER2-Expressing Advanced Colorectal Cancer

COH Protocol Number: 17493 ClinicalTrials.gov Number: NCT03201458

Principal Investigator: Vincent Chung, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-165, NCI#10139: A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma

COH Protocol Number: 17491

Principal Investigator: Saro Armenian, DO
Sponsor: Institutional

Title:  SC-PACS-001: Multi-Institutional Pilot Study to Assess the Needs of Childhood Cancer Survivors (CCS) Followed in Long-term Survivorship Clinics

COH Protocol Number: 17468 ClinicalTrials.gov Number: NCT03438318

Principal Investigator: Erminia Massarelli, MD, PhD
Sponsor: Industrial

Title:  A Multicenter, Two-Part, Phase 1b Clinical Study Of CMP-001 in Combination with Atezolizumab With and Without Radiation Therapy in Subjects with Advanced Non Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 17465 ClinicalTrials.gov Number: NCT03452137

Principal Investigator: Erminia Massarelli, MD, PhD
Sponsor: Industrial

Title:  A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

COH Protocol Number: 17457

Principal Investigator: Sunita Patel, PhD
Sponsor: Institutional

Title:  A Feasibility Study of Lifetime Stress and Effects on the Epigenome for Late-onset Breast Cancer Risk

COH Protocol Number: 17454 ClinicalTrials.gov Number: NCT03394755

Principal Investigator: Vinod Pullarkat, MD
Sponsor: Industrial

Title:  A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts

COH Protocol Number: 17450 ClinicalTrials.gov Number: NCT03008278

Principal Investigator: Joseph Chao, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-162, NCI#10066: A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)

COH Protocol Number: 17438 ClinicalTrials.gov Number: NCT03365882

Principal Investigator: Marwan Fakih, MD
Sponsor: Cooperative Group

Title:  SWOG S1613: A Randomized Phase II Study Of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification

COH Protocol Number: 17436 ClinicalTrials.gov Number: NCT01871727

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma

COH Protocol Number: 17434 ClinicalTrials.gov Number: NCT03399799

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564, a Humanized GPRC5D x CD3 DuoBody® Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17429 ClinicalTrials.gov Number: NCT03239392

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients with Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma

COH Protocol Number: 17428 ClinicalTrials.gov Number: NCT03440567

Principal Investigator: Robert Chen, MD
Sponsor: Institutional

Title:  A Phase I Study of Avelumab plus Utomilumab-based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

COH Protocol Number: 17422

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: Institutional

Title:  Feasibility of Longitudinal Blood Sample Collection in Patients Receiving Post Transplant Cyclophosphamide

COH Protocol Number: 17420 ClinicalTrials.gov Number: NCT03434379

Principal Investigator: Daneng Li, MD
Sponsor: Industrial

Title:  A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

COH Protocol Number: 17418 ClinicalTrials.gov Number: NCT03181126

Principal Investigator: Vinod Pullarkat, MD
Sponsor: Industrial

Title:  A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed Acute Lymphoblastic Leukemia

COH Protocol Number: 17416 ClinicalTrials.gov Number: NCT03418961

Principal Investigator: Joanne Mortimer, MD
Sponsor: Cooperative Group

Title:  SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.